FDA Approves Daiichi Sankyo’s Vanflyta for FLT3-ITD Positive AML Maintenance Treatment
The US Food and Drug Administration (FDA) has granted clearance to Japan-based Daiichi Sankyo (TYO:...
Gilead Sciences Halts Development of Magrolimab for HR-MDS Following Phase III Trial Results
Gilead Sciences (NASDAQ: GILD) has decided to stop pursuing the potential first-in-class immunotherapy, magrolimab, for...
EU Commits EUR 3 Million to Strengthen Healthcare Access in Latin America and Caribbean
The European Union (EU) has announced a EUR 3 million (USD 3.3 million) funding injection...
AbbVie’s Aquipta and Novartis’s Piqray Receive Regulatory Approvals in Mexico
Mexico’s Federal Commission for Protection against Health Risks (COFEPRIS) has granted registration approvals to two...
Oxford and Peking University Study Unveils Genetic Risk Factors in East Asian Population
Researchers from the UK’s Oxford Population Health and China’s Peking University have conducted a comprehensive...
Roche and Alnylam Partner on RNAi Therapeutic Zilebesiran for Hypertension Treatment
Swiss pharmaceutical giant Roche (SWX: ROG) has signed a deal with US-based RNAi specialist Alnylam...
Pfizer Ends Partnership with Syros Pharmaceuticals for Sickle Cell Disease Program
Syros Pharmaceuticals Inc., (NASDAQ: SYRS) has disclosed in an SEC filing that Pfizer (NYSE: PFE)...
Ascletis Pharma’s ASC22 Combo Therapy Shows Promise in HIV Functional Cure Clinical Trial
China-based Ascletis Pharma Inc., (HKG: 1672) has announced that the Shanghai Public Health Clinical Center...
Jiangsu Hengrui Pharmaceuticals and Hansoh Pharmaceutical Group Get NMPA Approval for Solid Tumor Treatment
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received clinical trial...
Taiwan’s TFDA Orders Recall of Two Nucala Batches Due to Glass Fragments
The Food and Drug Administration (FDA) bureau of Taiwan, part of Greater China, has issued...
Eli Lilly’s Mirikizumab and Chia Tai Tianqing’s Lanifibranor Enter Breakthrough Therapy Review
US pharmaceutical major Eli Lilly’s (NYSE: LLY) mirikizumab and China-based Chia Tai Tianqing’s lanifibranor have...
Amoy Diagnostics and AstraZeneca Expand Partnership for Companion Diagnostic Development
China-based Amoy Diagnostics Co., Ltd (AmoyDx, SHE: 300685) has announced an additional cooperation agreement with...
Vcanbio’s VUM02 Stem Cell Therapy Accepted for Review by China’s CDE for aGvHD Treatment
China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that the Center...
NMPA Updates List of Medical Devices Exempt from Clinical Evaluation in China
The National Medical Products Administration (NMPA) has released an updated version of the “List of...
Chinese Health Authorities Unveil Key Reform Tasks for Medical System in H2 2023
The National Health Commission (NHC), National Development and Reform Commission (NDRC), Ministry of Finance (MoF),...
NHSA Releases Official Guidelines for Drug Negotiations and Bidding for NRDL Update
The National Healthcare Security Administration (NHSA) has officially released the “Negotiation Drug Renewals” and “Non-exclusive...
Carbon Medical Technology Secures Over RMB 100 Million in Series A Financing for Interventional Therapy
Shenzhen-based Carbon Medical Technology Co., Ltd has reportedly raised over RMB 100 million (USD 13.9...
BeiGene’s Tislelizumab Receives Positive CHMP Opinion for Esophageal Cancer Treatment
BeiGene (NASDAQ: BGNE) has announced that its programmed death-1 (PD-1) inhibitor, tislelizumab, has received a...
CanSino Biologics Granted Approval by Health Canada for Zoster Vaccine Candidate CS-2032
China-based vaccines specialist CanSino Biologics Inc., (HKG: 6185) has announced receiving approval from Health Canada...
Bavarian Nordic’s RSV Vaccine Candidate Fails Phase III Trial, Discontinues Program
Denmark-based Bavarian Nordic A/S (CPH: BAVA) has revealed that its pipeline respiratory syncytial virus (RSV)...